PVRL2 Suppresses Anti-tumor Immunity Through PVRIG- and TIGIT-Independent Pathways
J. Yang, L. Wang, J. R. Byrnes, L. L. Kirkemo, H. Driks, C. Belair, O. A. Aguilar, L. L. Lanier, J. A. Wells, L. Fong, R. Blelloch
This study shows PVRL2 suppresses anti-tumor immunity independently of PVRIG and TIGIT, with deletion reducing tumor growth more than PD-L1 loss.
bioRxiv · Jan 26, 2024 · PreprintImmunology